What is claimed is:

1. An isolated antigen-binding protein, comprising HCDR3, HCDR2 and HCDR1, wherein said HCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 67, wherein said HCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 68 or SEQ ID NO: 11, and wherein said HCDR1 comprises an amino acid sequence as set forth in any one of SEQ ID NO: 2, SEQ ID NO: 10, and SEQ ID NO: 16~~comprising an HCDR3, wherein said HCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 67~~.
2. The isolated antigen-binding protein of claim 1, wherein said HCDR3 comprises an amino acid sequence as set forth in any one of SEQ ID NO: 4, SEQ ID NO: 12, and SEQ ID NO: 18, wherein said HCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 17, and wherein said HCDR1 comprises an amino acid sequence as set forth in any one of SEQ ID NO: 2, SEQ ID NO: 10, and SEQ ID NO: 16 ~~wherein said HCDR3 comprises an amino acid sequence as set forth in any one of SEQ ID NO: 4, SEQ ID NO: 12, and SEQ ID NO: 18~~.

~~3. The isolated antigen-binding protein of any one of claims 1-2, comprising an HCDR2, wherein said HCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 68 or SEQ ID NO: 11.~~

~~4. The isolated antigen-binding protein of claim 3, wherein said HCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 17.~~

~~5. The isolated antigen-binding protein of any one of claims 1-4, comprising an HCDR1, wherein said HCDR1 comprises an amino acid sequence as set forth in any one of SEQ ID NO: 2, SEQ ID NO: 10, and SEQ ID NO: 16.~~

~~6. The isolated antigen-binding protein of claim 5, comprising an H-FR1, wherein a C terminal of said H-FR1 is directly or indirectly linked to an N terminal of said HCDR1, and said H-FR1 comprises an amino acid sequence as set forth in SEQ ID NO: 72.~~

~~7. The isolated antigen-binding protein of claim 6, wherein said H-FR1 comprises an amino acid sequence as set forth in any one of SEQ ID NO: 34, SEQ ID NO: 43,~~

~~and SEQ ID NO: 49.~~

~~8. The isolated antigen-binding protein of any one of claims 5-7, comprising an H-FR2, wherein said H-FR2 is located between said HCDR1 and said HCDR2 and comprises an amino acid sequence as set forth in SEQ ID NO: 73.~~

~~9. The isolated antigen-binding protein of claim 8, wherein said H-FR2 comprises an amino acid sequence as set forth in SEQ ID NO: 35 or SEQ ID NO: 44.~~

~~10. The isolated antigen-binding protein of any one of claims 3-9, comprising an H-FR3, wherein said H-FR3 is located between said HCDR2 and said HCDR3 and comprises an amino acid sequence as set forth in SEQ ID NO: 80 or SEQ ID NO: 45.~~

~~11. The isolated antigen-binding protein of claim 10, wherein said H-FR3 comprises an amino acid sequence as set forth in SEQ ID NO: 36 or SEQ ID NO: 42.~~

~~12. The isolated antigen-binding protein of any one of claims 1-11, comprising an H-FR4, wherein an N terminal of said H-FR4 is linked to a C terminal of said HCDR3, and said H-FR4 comprises an amino acid sequence as set forth in SEQ ID NO: 74.~~

~~13. The isolated antigen-binding protein of claim 12, wherein said H-FR4 comprises an amino acid sequence as set forth in SEQ ID NO: 46 or SEQ ID NO: 37.~~

~~14.~~3. The isolated antigen-binding protein of ~~any one of claims 1-13~~claim 1, comprising a VH, wherein said VH comprises an amino acid sequence as set forth in SEQ ID NO: 78.

~~15.~~4. The isolated antigen-binding protein of claim ~~14~~3, wherein said VH comprises an amino acid sequence as set forth in any one of SEQ ID NO: 1, SEQ ID NO: 9, SEQ ID NO: 15, and SEQ ID NO: 19.

~~16.~~5. The isolated antigen-binding protein of ~~any one of claims 1-15~~claim 1, comprising LCDR3, LCDR2 and LCDR1, wherein said LCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 69, wherein said LCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 70, and wherein said LCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 71~~comprising an LCDR3, wherein said LCDR3 comprises an amino acid sequence as set forth in~~

~~SEQ ID NO: 69~~.

~~17.~~6. The isolated antigen-binding protein of claim ~~16~~5, wherein said LCDR3 comprises an amino acid sequence as set forth in any one of SEQ ID NO: 8, SEQ ID NO: 14, SEQ ID NO: 23, and SEQ ID NO: 25, wherein said LCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 7 or SEQ ID NO: 22, and wherein said LCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 6 or SEQ ID NO: 21~~wherein said LCDR3 comprises an amino acid sequence as set forth in any one of SEQ ID NO: 8, SEQ ID NO: 14, SEQ ID NO: 23, and SEQ ID NO: 25~~.

~~18. The isolated antigen-binding protein of any one of claims 1-17, comprising an LCDR2, wherein said LCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 70.~~

~~19. The isolated antigen-binding protein of claim 18, wherein said LCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 7 or SEQ ID NO: 22.~~

~~20. The isolated antigen-binding protein of any one of claims 1-19, comprising an LCDR1, wherein said LCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 71.~~

~~21. The isolated antigen-binding protein of claim 20, wherein said LCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 6 or SEQ ID NO: 21.~~

~~22. The isolated antigen-binding protein of any one of claims 20-21, comprising an L-FR1, wherein a C terminal of said L-FR1 is directly or indirectly linked to an N terminal of said LCDR1, and said L-FR1 comprises an amino acid sequence as set forth in SEQ ID NO: 75.~~

~~23. The isolated antigen-binding protein of claim 22, wherein said L-FR1 comprises an amino acid sequence as set forth in any one of SEQ ID NO: 38, SEQ ID NO: 47, SEQ ID NO: 50 and SEQ ID NO: 53.~~

~~24. The isolated antigen-binding protein of any one of claims 20-23, comprising an L-FR2, wherein said L-FR2 is located between said LCDR1 and said LCDR2 and comprises an amino acid sequence as set forth in SEQ ID NO: 39.~~

~~25. The isolated antigen-binding protein of any one of claims 18-24, comprising an L-FR3, wherein said L-FR3 is located between said LCDR2 and said LCDR3 and comprises an amino acid sequence as set forth in SEQ ID NO: 76.~~

~~26. The isolated antigen-binding protein of claim 25, wherein said L-FR3 comprises an amino acid sequence as set forth in any one of SEQ ID NO: 40, SEQ ID NO: 48, and SEQ ID NO: 51.~~

~~27. The isolated antigen-binding protein of any one of claims 16-26, comprising an L-FR4, wherein an N terminal of said L-FR4 is linked to a C terminal of the LCDR3, and said L-FR4 comprises an amino acid sequence as set forth in SEQ ID NO: 77.~~

~~28. The isolated antigen-binding protein of claim 27, wherein said L-FR4 comprises an amino acid sequence as set forth in any one of SEQ ID NO: 41, SEQ ID NO: 52, and SEQ ID NO: 54.~~

~~29.~~7. The isolated antigen-binding protein of ~~any one of claims 1-28~~claim 1, comprising a VL, wherein said VL comprises an amino acid sequence as set forth in SEQ ID NO: 79.

~~30.~~8. The isolated antigen-binding protein of claim ~~29~~7, wherein said VL comprises an amino acid sequence as set forth in any one of SEQ ID NO: 5, SEQ ID NO: 13, SEQ ID NO: 20, and SEQ ID NO: 24.

~~31.~~9. The isolated antigen-binding protein of ~~any one of claims 1-30~~claim 1, comprising any set of amino acid sequences selected from the group consisting of:

1) said VH comprising the amino acid sequence as set forth in SEQ ID NO: 1 and said VL comprising the amino acid sequence as set forth in SEQ ID NO: 5;
2) said VH comprising the amino acid sequence as set forth in SEQ ID NO: 15 and said VL comprising the amino acid sequence as set forth in SEQ ID NO: 5;
3) said VH comprising the amino acid sequence as set forth in SEQ ID NO: 9 and said VL comprising the amino acid sequence as set forth in SEQ ID NO: 13;
4) said VH comprising the amino acid sequence as set forth in SEQ ID NO: 19 and said VL comprising the amino acid sequence as set forth in SEQ ID NO: 20; or
5) said VH comprising the amino acid sequence as set forth in SEQ ID NO: 19 and

said VL comprising the amino acid sequence as set forth in SEQ ID NO: 24.

~~32.~~10. The isolated antigen-binding protein of ~~any one of claims 1-31~~claim 1, comprising an antibody heavy chain constant region.

~~33. The isolated antigen-binding protein of claim 32, wherein said antibody heavy chain constant region is derived from a human IgG heavy chain constant region.~~

~~34.~~11. The isolated antigen-binding protein of ~~any one of claims 32-33~~claim 10, wherein said antibody heavy chain constant region is derived from a human IgG1 heavy chain constant region.

~~35.~~12. The isolated antigen-binding protein of ~~any one of claims 1-34~~ claim 1, comprising an antibody light chain constant region.

~~36.~~13. The isolated antigen-binding protein of claim ~~35~~12, wherein said antibody light chain constant region is derived from a human Igκ constant region.

~~37. The isolated antigen-binding protein of any one of claims 1-36, comprising an antibody or an antigen-binding fragment thereof.~~

~~38. The isolated antigen-binding protein of claim 37, wherein said antigen-binding fragment comprises Fab, Fab', Fv fragment, $F(ab')_2$, $F(ab)_2$, scFv, di-scFv, and/or dAb.~~

~~39. The isolated antigen-binding protein of any one of claims 37-38, wherein said antibody is selected from one or more groups consisting of: a monoclonal antibody, a chimeric antibody, a humanized antibody, and a fully human antibody.~~

~~40. The isolated antigen-binding protein of any one of claims 1-39, substantially not competing with a reference antibody for binding to CLDN18.2, as verified in FACS, wherein said reference antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), the VH of said reference antibody comprises an amino acid sequence as set forth in SEQ ID NO: 55, and the VL of said reference antibody comprises an amino acid sequence as set forth in SEQ ID NO: 56.~~

~~41. The isolated antigen-binding protein of any one of claims 1-40, specifically binding to CLDN18.2 and not substantially binding to CLDN18.1.~~

~~42. The isolated antigen-binding protein of any one of claims 40-41, wherein said~~

~~CLDN18.2 comprises mouse CLDN18.2, cynomolgus monkey CLDN18.2, and/or human CLDN18.2.~~

~~43. The isolated antigen-binding protein of any one of claims 1-42, having CDC activity.~~

~~44. The isolated antigen-binding protein of any one of claims 1-43, capable of inhibiting tumor growth and/or proliferation of tumor cells.~~

~~45.~~14. A chimeric antigen receptor, comprising a targeting moiety, wherein said targeting moiety comprises the antigen-binding protein of any one of claims ~~1-44~~1-13.

~~46.~~15. The chimeric antigen receptor of claim ~~45~~14, comprising a costimulatory domain, an intracellular signaling domain, a transmembrane region, a hinge region between the targeting moiety and the transmembrane region, and a signal peptide; wherein said costimulatory domain comprises a costimulatory domain derived from one or more proteins selected from the group consisting of: CD28, 4-1BB, CD27, CD2, CD7, CD8, OX40, CD226, DR3, SLAM, CDS, ICAM-1, NKG2D, NKG2C, B7-H3, 2B4, FcεRIγ, BTLA, GITR, HVEM, DAP10, DAP12, CD30, CD40, CD40L, TIM1, PD-1, LFA-1, LIGHT, JAML, CD244, CD100, ICOS, a ligand of CD83, CD40, and MyD88, wherein said intracellular signaling domain comprising an intracellular signaling domain derived from one or more proteins selected from the group consisting of: CD3ζ, CD3δ, CD3γ, CD3ε, CD79a, CD79b, FcεRIγ, FcεRIβ, FcγRIIa, bovine leukemia virus gp30, Epstein-Barr virus (EBV) LMP2A, simian immunodeficiency virus PBj14Nef, Kaposi's Sarcoma Associated-Herpesvirus (HSKV), DAP10, DAP-12, and a domain containing at least one ITAM, wherein said transmembrane region comprises a transmembrane domain derived from one or more proteins selected from the group consisting of: CD8, CD28, 4-1BB, CD4, CD27, CD7, PD-1, TRAC, TRBC, CD3ε, CD3ζ, CTLA-4, LAG-3, CD5, ICOS, OX40, NKG2D, 2B4, CD244, FcεRIγ, BTLA, CD30, GITR, HVEM, DAP10, CD2, NKG2C, LIGHT, DAP12, CD40L, TIM1, CD226, DR3, CD45, CD80, CD86, CD9, CD16, CD22, CD33, CD37, CD64, CD134, CD137, CD154, and SLAM, wherein said hinge region comprises a hinge region derived from one

or more proteins selected from the group consisting of: CD28, IgG1, IgG4, IgD, 4-1BB, CD4, CD27, CD7, CD8, PD-1, ICOS, OX40, NKG2D, NKG2C, FcεRIγ, BTLA, GITR, DAP10, CD40L, TIM1, CD226, SLAM, CD30, and LIGHT~~comprising a costimulatory domain, wherein said costimulatory domain comprises a costimulatory domain derived from one or more proteins selected from the group consisting of: CD28, 4-1BB, CD27, CD2, CD7, CD8, OX40, CD226, DR3, SLAM, CDS, ICAM-1, NKG2D, NKG2C, B7-H3, 2B4, FcεRIγ, BTLA, GITR, HVEM, DAP10, DAP12, CD30, CD40, CD40L, TIM1, PD-1, LFA-1, LIGHT, JAML, CD244, CD100, ICOS, a ligand of CD83, CD40, and MyD88~~.

~~47.~~16. The chimeric antigen receptor of ~~any one of claims 45-46~~claim 15, wherein said costimulatory domain is an intracellular costimulatory signaling region derived from 4-1BB comprising an amino acid sequence as set forth in SEQ ID NO: 85, wherein said intracellular signaling domain is a signaling domain derived from CD3ζ comprising an amino acid sequence as set forth in SEQ ID NO: 86, wherein said transmembrane region is a transmembrane region derived from CD8 comprising an amino acid sequence as set forth in SEQ ID NO: 84, wherein said hinge region is a hinge region derived from CD8 comprising an amino acid sequence as set forth in SEQ ID NO: 83, wherein said signal peptide is a signal peptide derived from the CD8 protein comprising an amino acid sequence as set forth in SEQ ID NO: 88~~wherein said costimulatory domain is an intracellular costimulatory signaling region derived from 4-1BB~~.

~~48. The chimeric antigen receptor of any one of claims 46-47, wherein said costimulatory domain comprises an amino acid sequence as set forth in SEQ ID NO: 85.~~

~~49. The chimeric antigen receptor of any one of claims 45-48, comprising an intracellular signaling domain, wherein said intracellular signaling domain comprising an intracellular signaling domain derived from one or more proteins selected from the group consisting of: CD3ζ, CD3δ, CD3γ, CD3ε, CD79a, CD79b, FcεRIγ, FcεRIβ, FcγRIIa, bovine leukemia virus gp30, Epstein-Barr virus (EBV)~~

~~LMP2A, simian immunodeficiency virus PBj14Nef, Kaposi's Sarcoma Associated-Herpesvirus (HSKV), DAP10, DAP-12, and a domain containing at least one ITAM.~~

~~50. The chimeric antigen receptor of claim 49, wherein said intracellular signaling domain is a signaling domain derived from CD3ζ.~~

~~51. The chimeric antigen receptor of any one of claims 49-50, wherein said intracellular signaling domain comprises an amino acid sequence as set forth in SEQ ID NO: 86.~~

~~52. The chimeric antigen receptor of any one of claims 45-51, comprising a transmembrane region, wherein said transmembrane region comprises a transmembrane domain derived from one or more proteins selected from the group consisting of: CD8, CD28, 4-1BB, CD4, CD27, CD7, PD-1, TRAC, TRBC, CD3ε, CD3ζ, CTLA-4, LAG-3, CD5, ICOS, OX40, NKG2D, 2B4, CD244, FcεRIγ, BTLA, CD30, GITR, HVEM, DAP10, CD2, NKG2C, LIGHT, DAP12, CD40L, TIM1, CD226, DR3, CD45, CD80, CD86, CD9, CD16, CD22, CD33, CD37, CD64, CD134, CD137, CD154, and SLAM.~~

~~53. The chimeric antigen receptor of claim 52, wherein said transmembrane region is a transmembrane region derived from CD8.~~

~~54. The chimeric antigen receptor of any one of claims 52-53, wherein said transmembrane region comprises an amino acid sequence as set forth in SEQ ID NO: 84.~~

~~55. The chimeric antigen receptor of any one of claims 45-54, comprising a hinge region between the targeting moiety and the transmembrane region, wherein said hinge region comprises a hinge region derived from one or more proteins selected from the group consisting of: CD28, IgG1, IgG4, IgD, 4-1BB, CD4, CD27, CD7, CD8, PD-1, ICOS, OX40, NKG2D, NKG2C, FcεRIγ, BTLA, GITR, DAP10, CD40L, TIM1, CD226, SLAM, CD30, and LIGHT.~~

~~56. The chimeric antigen receptor of claim 55, wherein said hinge region is a hinge region derived from CD8.~~

~~57. The chimeric antigen receptor of any one of claims 55-56, wherein said hinge region comprises an amino acid sequence as set forth in SEQ ID NO: 83.~~

~~58. The chimeric antigen receptor of any one of claims 45-57, further comprising a signal peptide.~~

~~59. The chimeric antigen receptor of claim 58, wherein said signal peptide is a signal peptide derived from the CD8 protein.~~

~~60. The chimeric antigen receptor of any one of claims 58-59, wherein said signal peptide comprises an amino acid sequence as set forth in SEQ ID NO: 88.~~

~~61.~~17. The chimeric antigen receptor of ~~any one of claims 45-60~~claim 14, further comprising a low-density lipoprotein receptor-related protein or a fragment thereof.

~~62.~~18. The chimeric antigen receptor of claim ~~61~~17, wherein said low-density lipoprotein receptor-related protein or the fragment thereof comprises one or more groups selected from: low-density lipoprotein receptor-related proteins 1-12 and functional fragments thereof.

~~63.~~19. The chimeric antigen receptor of ~~any one of claims 61-62~~claim 17, wherein said low-density lipoprotein receptor-related protein or the fragment thereof comprises an amino acid sequence as set forth in SEQ ID NO: 91.

~~64.~~20. A polypeptide molecule comprising the isolated antigen-binding protein of any one of claims ~~1-44~~1-13 or the chimeric antigen receptor of any one of claims ~~45-63~~14-19.

~~65. The polypeptide molecule of claim 64, comprising a fusion protein.~~

~~66.~~21. An immunoconjugate, comprising the isolated antigen-binding protein of any one of claims ~~1-46~~1-13.

~~67.~~22. One or more isolated nucleic acid molecules, encoding the isolated antigen-binding protein of any one of claims ~~1-44~~1-13, the chimeric antigen receptor of any one of claims ~~45-63~~14-19 or the polypeptide molecule of ~~any one of claims 64-65~~claim 20.

~~68. The nucleic acid molecule of claim 67, comprising a nucleotide sequence as set forth in any one of SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, and SEQ ID NO: 33.~~

~~69. The nucleic acid molecule of any of claims 67-68, comprising any set of nucleotide~~

~~sequences selected from the groups consisting of :~~

~~1) a nucleotide sequence as set forth in SEQ ID NO: 26 and a nucleotide sequence as set forth in SEQ ID NO: 27;~~

~~2) a nucleotide sequence as set forth in SEQ ID NO: 30 and a nucleotide sequence as set forth in SEQ ID NO: 27;~~

~~3) a nucleotide sequence as set forth in SEQ ID NO: 28 and a nucleotide sequence as set forth in SEQ ID NO: 29;~~

~~4) a nucleotide sequence as set forth in SEQ ID NO: 31 and a nucleotide sequence as set forth in SEQ ID NO: 32; or~~

~~5) a nucleotide sequence as set forth in SEQ ID NO: 31 and a nucleotide sequence as set forth in SEQ ID NO: 33.~~

~~70. A vector, comprising the nucleic acid molecule of any one of claims 67-69.~~

~~71.~~ A cell, comprising the isolated antigen-binding protein of any one of claims ~~1-44~~1-13, the chimeric antigen receptor of any one of claims ~~45-63~~14-19, the polypeptide molecule of ~~any one of claims 64-65~~claim 20, or the nucleic acid molecule of ~~any one of~~ claims ~~67-69~~22~~, or the vector of claim 70~~.

~~72.~~23. ~~The cell of claim 71, which is an immune effector cell.~~

~~73. The cell of any one of claims 71-72, comprising a T cell, a B cell, a natural killer cell (NK cell), a macrophage, an NKT cell, a monocyte, a dendritic cell, a granulocyte, a lymphocyte, a leukocyte, a peripheral blood mononuclear cell, an embryonic stem cell, a lymphoid progenitor cell, and/or a pluripotent stem cell.~~

~~74. The cell of any one of claims 71-73, which is a T cell.~~

~~75. The cell of any one of claims 71-74, further comprising and/or expressing a low-density lipoprotein receptor-related protein or a fragment thereof.~~

~~76. The cell of claim 75, wherein said low-density lipoprotein receptor-related protein or the fragment thereof comprises one or more groups selected from: low-density lipoprotein receptor-related proteins 1-12 and functional fragments thereof.~~

~~77. The cell of any one of claims 75-76, wherein said low-density lipoprotein receptor-related protein or the fragment thereof is low-density lipoprotein receptor-related~~

protein 5 and/or 6 or a fragment thereof.

78. The cell of any one of claims 75-77, wherein said low-density lipoprotein receptor-related protein or the fragment thereof comprises an amino acid sequence as set forth in SEQ ID NO: 91.

79.24. A pharmaceutical composition, comprising the isolated antigen-binding protein of any one of claims 1-441-13, the chimeric antigen receptor of any one of claims 45-6314-19, the polypeptide molecule of any one of claims 64-65claim 20, the immunoconjugate of claim 6621, the nucleic acid molecule of any one of claims 67-69claim 22, the vector of claim 70, and/or the cell of any one of claims 71-78claim 23, and optionally a pharmaceutically acceptable carrier.

80. A method for preparing the isolated antigen-binding protein of any one of claims 1-44, said method comprising: culturing the cell of claim 71, under the condition that the antigen-binding protein is expressed.

81.25. A uUse of the an isolated antigen-binding protein of any one of claims 1-441-13, the a chimeric antigen receptor of any one of claims 45-6314-19, the a polypeptide molecule of any one of claims 64-65claim 20, the an immunoconjugate of claim 6621, the a nucleic acid molecule of any one of claims 67-69claim 22, the vector of claim 70, the a cell of any one of claims 71-78claim 23, and/or the a pharmaceutical composition of claim 7924, in the manufacture of a medicament , , wherein said medicament is used for the prevention, alleviation and/or treatment of a disease and/or a disorder.

82.26. The use of claim 8125, wherein said disease and/or the disorder comprises cancers.

83.27. The use of any one of claims 81-82claim 26, wherein said cancers comprise solid tumors and/or hematomas.

84.28. The use of claim 26The use of any one of claims 82-83, wherein said cancers comprise gastric cancer and/or colon cancer.

85. A method for detecting CLDN18.2 in a sample, said method comprising: administering the isolated antigen-binding protein of any one of claims 1-44, the

~~chimeric antigen receptor of any one of claims 45-63, the polypeptide molecule of any one of claims 64-65, the immunoconjugate of claim 66, the nucleic acid molecule of any one of claims 67-69, the vector of claim 70, the cell of any one of claims 71-78, and/or the pharmaceutical composition of claim 79.~~

~~86.~~ ~~A reagent or a kit for detecting CLDN18.2 in a sample, comprising the isolated antigen-binding protein of any one of claims 1-44, the chimeric antigen receptor of any one of claims 45-63, the polypeptide molecule of any one of claims 64-65, the immunoconjugate of claim 66, the nucleic acid molecule of any one of claims 67-69, the vector of claim 70, the cell of any one of claims 71-78, and/or the pharmaceutical composition of claim 79.~~

~~87.~~ ~~A use of the isolated antigen-binding protein of any one of claims 1-44, the chimeric antigen receptor of any one of claims 45-63, the polypeptide molecule of any one of claims 64-65, the immunoconjugate of claim 66, the nucleic acid molecule of any one of claims 67-69, the vector of claim 70, the cell of any one of claims 71-78, and/or the pharmaceutical composition of claim 79 in preparation of a kit, wherein said kit is used for detecting the presence and/or content of CLDN18.2 in a sample.~~